---
title: "Oura IPO Postponed: 2026 Status, $11B Valuation and Funding History"
description: "Oura delayed its September 2026 IPO. Compare its $11B Series E valuation with its proposed $13.5B IPO value and learn what happens next."
date: 2026-10-29T00:00:00.000Z
source: https://venturecapitaltracker.com/oura-ipo-postponed-2026-valuation-funding
---

# Oura IPO Postponed: 2026 Status, $11B Valuation and Funding History

> Oura delayed its September 2026 IPO. Compare its $11B Series E valuation with its proposed $13.5B IPO value and learn what happens next.

**Oura has not gone public.** The smart-ring company postponed its planned Nasdaq IPO on **September 29, 2026**, citing uncertainty in the IPO market. It had marketed a preliminary **$40–$44 share-price range**, but the deal was not priced or completed. The difference between its **$11 billion 2025 private valuation** and a roughly **$13.5 billion implied IPO valuation** is central to understanding the news.

## Oura IPO: key facts

| Question | Current answer |
| --- | --- |
| Is Oura stock trading publicly? | **No**, its planned offering was postponed |
| What happened? | IPO delayed September 29, 2026 |
| Preliminary IPO range | **$40–$44 per share** |
| Indicative offering | 50M shares, roughly **$2.1B** at midpoint, per Reuters/Axios |
| Implied planned valuation | Approximately **$13.5B** at midpoint, **not achieved** |
| Last completed major private financing | **Over $900M Series E** in October 2025 |
| Last company-disclosed private valuation | Approximately **$11B** |
| Paid members | **5.7M** at the IPO delay; October reporting said **over 6M** |

Numbers refer to different reporting dates and should not be added together. In particular, a proposed market capitalization is **not** a private financing round or a realized public valuation.

## Why did Oura postpone the offering?

Oura said it delayed the IPO despite investor demand because of market uncertainty. Reporting from Reuters, Axios and AP described volatile IPO pricing conditions. Investors were also assessing the relative appeal of a hardware-plus-subscription wearable business compared with software and health-tech companies.

An important detail: **a large majority of the proposed shares were to be sold by existing shareholders**, not issued as new shares to fund the company. That shapes the deal's economics. A successful IPO with many secondary shares can provide liquidity to existing holders without adding the same amount of new cash to the company.

The company did not announce a replacement listing date in its September 29 statement.

## Oura valuation history

| Financing or milestone | Value | Meaning |
| --- | --- | --- |
| Dec 19, 2024 Series D | **$200M raised; $5.2B valuation** | Completed private financing |
| Oct 14, 2025 Series E | **>$900M raised; ~$11B valuation** | Completed private financing |
| Sep 2026 proposed IPO | **~$13.5B at the indicative midpoint** | Planned equity value, **not** an achieved market cap |
| Sep 29, 2026 | **IPO postponed** | No completed public offering valuation |

The 2025 Series E was led by Fidelity Management & Research Company, with ICONIQ, Whale Rock and Atreides participating. Alumni Ventures is a portfolio investor, but the Series E announcement does not establish whether AV invested in that round.

## Why Oura attracted attention

[Oura](/startup/oura) combines a **smart ring** with an app and subscription offering health and wellness insights. Its strategy depends not just on selling wearable hardware, but on keeping users engaged and paying for ongoing insights.

Oura disclosed **5.7 million paid members** around its September IPO postponement, and Wall Street Journal reporting on October 22 said membership exceeded 6 million. These figures are company-reported and refer to different dates.

The company reported **$907.9 million of revenue for fiscal 2025**, according to coverage of its prospectus, and said it expected fiscal 2026 revenue growth of roughly 90%. The business is exposed to hardware margins, product renewal cycles, competition and the economics of subscription retention.

## Is Oura comparable to Apple, Whoop or Samsung?

| Alternative | Product | Main difference |
| --- | --- | --- |
| Apple Watch | Smartwatch | Broader computing ecosystem; larger device with screen |
| Samsung Galaxy Ring | Smart ring | Tied to Samsung's wider consumer ecosystem |
| Ultrahuman | Smart ring | Competes more directly on ring metrics, subscriptions and platform |
| Whoop | Fitness wearable | Different form factor and subscription-first performance offering |

Oura may receive a health-technology premium from investors because its long-term biometric data and subscriptions create recurring value. However, medical-adjacent functionality is **not itself proof** of medical-device economics, regulatory approval for every feature or sustained software-like margins.

## What does this mean for Alumni Ventures?

[Alumni Ventures](/fund/alumni-ventures) lists Oura in its official 2026 APEX portfolio. A postponed IPO is **not an exit**; a current investment remains private until liquidity occurs. No public offering proceeds or share-sale return should be attributed to AV from the withdrawn September timetable.

Even if a future offering eventually values Oura above its 2025 private round, that will not establish AV's investment multiple without knowing its entry price, ownership, dilution, fees and actual sale proceeds.

## What would change this page?

A new public prospectus or pricing range, an updated SEC registration, a new company-confirmed date, a completed IPO or further independently reported financial results would all require a refreshed assessment.

**Bottom line:** The private **$11B financing valuation is real historical deal evidence**. The much-discussed **$13.5B IPO value was only indicative**, and Oura has remained private following its September 2026 postponement.

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.